AR088585A1 - Un medicamento para tratar la enfermedad del ojo anterior - Google Patents
Un medicamento para tratar la enfermedad del ojo anteriorInfo
- Publication number
- AR088585A1 AR088585A1 ARP120104065A ARP120104065A AR088585A1 AR 088585 A1 AR088585 A1 AR 088585A1 AR P120104065 A ARP120104065 A AR P120104065A AR P120104065 A ARP120104065 A AR P120104065A AR 088585 A1 AR088585 A1 AR 088585A1
- Authority
- AR
- Argentina
- Prior art keywords
- eye disease
- treat
- medicinal product
- previous eye
- previous
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000607 artificial tear Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 229950004535 rebamipide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011240177 | 2011-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088585A1 true AR088585A1 (es) | 2014-06-18 |
Family
ID=47215697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104065A AR088585A1 (es) | 2011-11-01 | 2012-10-31 | Un medicamento para tratar la enfermedad del ojo anterior |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140294991A1 (enExample) |
| EP (1) | EP2773350A1 (enExample) |
| JP (1) | JP6060168B2 (enExample) |
| KR (1) | KR101951511B1 (enExample) |
| CN (1) | CN103945846A (enExample) |
| AR (1) | AR088585A1 (enExample) |
| AU (1) | AU2012333448A1 (enExample) |
| BR (1) | BR112014010376A2 (enExample) |
| CA (1) | CA2851095A1 (enExample) |
| CO (1) | CO6960545A2 (enExample) |
| EA (1) | EA201490721A1 (enExample) |
| HK (1) | HK1198811A1 (enExample) |
| IL (1) | IL231922A0 (enExample) |
| IN (1) | IN2014CN03123A (enExample) |
| MX (1) | MX2014005209A (enExample) |
| PH (1) | PH12014500967A1 (enExample) |
| SG (1) | SG11201401502TA (enExample) |
| TW (1) | TW201322982A (enExample) |
| WO (1) | WO2013065866A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6081173B2 (ja) * | 2011-12-12 | 2017-02-15 | ロート製薬株式会社 | 眼科用水性組成物 |
| TW201417814A (zh) * | 2012-09-28 | 2014-05-16 | Otsuka Pharma Co Ltd | 包括瑞巴派特之醫藥組成物 |
| JP6267003B2 (ja) * | 2014-02-27 | 2018-01-24 | 参天製薬株式会社 | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 |
| JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Ｌｔｔバイオファーマ | ドライアイ改善剤 |
| KR20170039347A (ko) | 2015-10-01 | 2017-04-11 | 삼진제약주식회사 | 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법 |
| GB201618175D0 (en) * | 2016-10-27 | 2016-12-14 | Warneford Healthcare Ltd | Pharmaceutical compositions |
| KR101840256B1 (ko) * | 2017-09-21 | 2018-03-21 | 대우제약 주식회사 | 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법 |
| KR101923519B1 (ko) | 2018-06-26 | 2019-02-27 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
| KR20200019451A (ko) | 2018-08-14 | 2020-02-24 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
| KR20210107607A (ko) | 2018-12-26 | 2021-09-01 | 라이온 가부시키가이샤 | 안과용 조성물 |
| WO2023054669A1 (ja) * | 2021-09-30 | 2023-04-06 | ロート製薬株式会社 | 眼科組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6084225A (ja) * | 1983-10-17 | 1985-05-13 | Hiroko Shimizu | 点眼剤 |
| JPH0723317B2 (ja) * | 1988-03-17 | 1995-03-15 | 生化学工業株式会社 | 角膜上皮層障害症治療剤 |
| AR004214A1 (es) * | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
| JP3093661B2 (ja) * | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| US8388995B1 (en) * | 2006-02-03 | 2013-03-05 | Auburn University | Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform |
| TWI415629B (zh) | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 |
| BRPI0720089A2 (pt) * | 2006-12-11 | 2013-12-24 | Sigma Tau Ind Farmaceuti | Uso de l-carnitina para a preparação de um medicamento na forma de colírio para o tratamento de doenças da córnea |
| WO2008074853A1 (en) * | 2006-12-21 | 2008-06-26 | Novartis Ag | Ophthalmic rebamipide solution |
| JP5441934B2 (ja) * | 2008-06-19 | 2014-03-12 | 大塚製薬株式会社 | レバミピドの医薬組成物 |
| US20120003296A1 (en) * | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
| US20110021974A1 (en) * | 2010-10-05 | 2011-01-27 | Shantha Totada R | Retinitis pigmentosa treatment and prophalaxis |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
-
2012
- 2012-10-29 TW TW101139895A patent/TW201322982A/zh unknown
- 2012-10-31 SG SG11201401502TA patent/SG11201401502TA/en unknown
- 2012-10-31 BR BR112014010376A patent/BR112014010376A2/pt not_active IP Right Cessation
- 2012-10-31 AU AU2012333448A patent/AU2012333448A1/en not_active Abandoned
- 2012-10-31 PH PH1/2014/500967A patent/PH12014500967A1/en unknown
- 2012-10-31 WO PCT/JP2012/078769 patent/WO2013065866A1/en not_active Ceased
- 2012-10-31 CA CA2851095A patent/CA2851095A1/en not_active Abandoned
- 2012-10-31 CN CN201280053483.0A patent/CN103945846A/zh active Pending
- 2012-10-31 IN IN3123CHN2014 patent/IN2014CN03123A/en unknown
- 2012-10-31 KR KR1020147014332A patent/KR101951511B1/ko active Active
- 2012-10-31 US US14/355,375 patent/US20140294991A1/en not_active Abandoned
- 2012-10-31 MX MX2014005209A patent/MX2014005209A/es not_active Application Discontinuation
- 2012-10-31 JP JP2014538080A patent/JP6060168B2/ja active Active
- 2012-10-31 EA EA201490721A patent/EA201490721A1/ru unknown
- 2012-10-31 AR ARP120104065A patent/AR088585A1/es unknown
- 2012-10-31 EP EP12788303.1A patent/EP2773350A1/en not_active Withdrawn
- 2012-10-31 HK HK14112267.5A patent/HK1198811A1/xx unknown
-
2014
- 2014-04-03 IL IL231922A patent/IL231922A0/en unknown
- 2014-05-14 CO CO14103881A patent/CO6960545A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014532641A (ja) | 2014-12-08 |
| BR112014010376A2 (pt) | 2017-04-25 |
| CO6960545A2 (es) | 2014-05-30 |
| IL231922A0 (en) | 2014-05-28 |
| KR20140087030A (ko) | 2014-07-08 |
| TW201322982A (zh) | 2013-06-16 |
| HK1198811A1 (en) | 2015-06-12 |
| PH12014500967A1 (en) | 2019-10-07 |
| MX2014005209A (es) | 2014-05-28 |
| CA2851095A1 (en) | 2013-05-10 |
| EA201490721A1 (ru) | 2014-08-29 |
| CN103945846A (zh) | 2014-07-23 |
| SG11201401502TA (en) | 2014-09-26 |
| EP2773350A1 (en) | 2014-09-10 |
| WO2013065866A1 (en) | 2013-05-10 |
| AU2012333448A1 (en) | 2014-05-22 |
| IN2014CN03123A (enExample) | 2015-07-03 |
| US20140294991A1 (en) | 2014-10-02 |
| JP6060168B2 (ja) | 2017-01-11 |
| KR101951511B1 (ko) | 2019-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EP4374873A3 (en) | Methods for treating or preventing opthalmological conditions | |
| PH12015500407B1 (en) | Methods of treating hypertriglyceridemia | |
| CL2017001117A1 (es) | Métodos para tratar enfermedades oculares. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| PH12014500967A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| MX2022002306A (es) | Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos. | |
| MX387839B (es) | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX380088B (es) | Uso terapéutico de una solución oftálmica acuosa estéril. | |
| AR094196A1 (es) | Composicion para el cuidado oral, kit, metodo de fabricacion | |
| MX384567B (es) | Preparacion oftalmologica | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |